A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 164
- Registration Number
- NCT04266795
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UC Irvine Medical Center, Orange, California, United States
A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 51
- Registration Number
- NCT04253314
- Locations
- 🇷🇺
Moscow State budget healthcare /ID# 218569, Moscow, Moskva, Russian Federation
🇷🇺Saratov State Medical University n.a. V.I. Razumovskiy /ID# 226059, Saratov, Saratovskaya Oblast, Russian Federation
🇷🇺Hematology department State budgetary health care institution Volgograd region /ID# 229813, Volgograd, Volgogradskaya Oblast, Russian Federation
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
- Interventions
- Drug: granulocyte colony-stimulating factor (G-CSF)
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04240002
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇩🇪Site DE49004, Essen, Nordrhein-Westfalen, Germany
🇮🇹SIte IT39001, Roma, Italy
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 90
- Registration Number
- NCT04230265
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
🇩🇪Klinikum der Universität München, Munich, Bavaria, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes(MDS)
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- TJ Biopharma Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT04202003
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Peking University International Hospital, Beijing, Beijing, China
🇨🇳Beijing Boren Hospital, Beijing, Beijing, China
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Cancer
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 465
- Registration Number
- NCT04161885
- Locations
- 🇺🇸
Arizona Oncology - Scottsdale - Cancer Transplant Institute /ID# 239711, Scottsdale, Arizona, United States
🇺🇸University of Arizona Cancer Center - Tucson /ID# 242507, Tucson, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences /ID# 239804, Little Rock, Arkansas, United States
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT04155580
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Smilow Cancer Hospital, New Haven, Connecticut, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04113616
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Mount Sinai, New York, New York, United States
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 273
- Registration Number
- NCT04107727
- Locations
- 🇪🇸
Complejo Hospitalario Universitario de A Coruña, Santiago de Compostela, A Coruña, Spain
🇪🇸Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 112
- Registration Number
- NCT04102020
- Locations
- 🇺🇸
Mitchell Cancer Institute /ID# 216443, Mobile, Alabama, United States
🇺🇸Compassionate Cancer Care Research Group - Fountain Valley /ID# 216156, Fountain Valley, California, United States
🇺🇸University of California, Los Angeles /ID# 219149, Los Angeles, California, United States